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Bexarotene (Targretin®), was registered for the treat-
ment of cutaneous T-cell lymphoma (CTCL) in 2002, 
and has been reported to induce a 45% overall response. 
Responses are mostly partial or generate a stable, skin-
restricted disease. This study explored the usefulness of 
a novel cancer-associated gene, NAV3 and corresponding 
chromosome 12 copy numbers as possible biomarkers 
to monitor the therapeutic response to bexarotene in 21 
Finnish patients with CTCL. Six patients (29%) reached 
complete remission (CR) and 3 of these remained in CR 
for more than 24 months, 12 (57%) reached a partial 
response (PR, with one stable disease) and 3 were non-
responders. Low-level NAV3 deletions were detected 
using a fluorescence in-situ hybridization (FISH) assay 
in the lesions of 5 patients, 4 of whom were non-respon-
ders or progressed after short PR. This occurrence of 
NAV3 deletions was statistically significant compared 
with non-progressors (p = 0.011, Fisher’s exact test). 
Chromosome 12 tetraploidy was found in the lesions of 
two of the 3 patients with CR who remained in remission. 
While such tetraploidy is a feature of proliferating nor-
mal T cells, this observation may reflect a favourable an-
ti-tumour immune response among the skin-infiltrating 
lymphocytes. Key words: bexarotene; NAV3, cutaneous 
T-cell lymphoma; mycosis fungoides; Sézary syndrome; 
clinical response. 
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Cutaneous T-cell lymphoma (CTCL) is a malignancy of 
mature T cells (CD3+, CD4+, CD45RO+, CD30–, CLA+), 
primarily affecting the skin. There are 8 subtypes of 
CTCL (1), the most common being mycosis fungoides 
(MF), primary skin CD30+ lymphoproliferative disease 
and Sézary syndrome (SS). Chromosomal instability is 
a typical feature of CTCL (reviewed in 2, 3). There is 
currently no disease-specific targeted therapy for CTCL 
although therapy with monoclonal antibodies targeting 
either CD52 (alemtuzumab), IL2R (denileukin diftitox) or 
CD4 molecules (zanolimumab) are used (4). The current 
modes of therapy either induce apoptosis of malignant 
cells (psoralen plus ultraviolet A (PUVA), extracorporeal 
photopheresis (ECP), retinoic acid) or induce cytotoxicity 
(monoclonal antibodies, interferon (IFN)). 
During the past decade, a new group of retinoids, 
the rexinoids, has proven useful in treatment of CTCL. 
Bexarotene (Targretin®) is a retinoid-X receptor (RXR)-
selective retinoid (5), and is registered in Europe for 
stage IIb–IVb MF. Bexarotene induces apoptosis, and 
inhibits proliferation (through transforming growth 
factor-beta (TGF-β)) of the malignant cells (5, 6). 
Clinically, a 45% overall response has been achieved 
(7–10). The responses are mostly partial or generate a 
stable disease, while complete responses are seen in less 
than 10% of patients (10). The duration of the clinical 
response is highly variable, with a median of 8 months 
(10). There is no suitable biomarker available either 
for the selection of patients who are likely to respond 
to bexarotene or for the monitoring of the therapeutic 
response. 
In relation to an eventual molecular biomarker, we 
have observed previously that allelic deletion of NAV3 
(neuronal navigator 3, also called POMFIL1), a can-
didate cancer gene, is frequent in CTCL (11, 12). With 
the array-comparative genomic hybridization technique, 
NAV3 deletions have been observed with a frequency 
of 20–30% in CTCL patients (13), while 12q deletions, 
not specific for NAV3, were reported in another CTCL 
patient cohort (14). NAV3 is a spliced gene (40 exons) 
located in c12q21.1 and expressed in brain tissue, ac-
tivated T cells, placenta, colon and certain cancer cell 
lines (11, 15, 16). Accumulating evidence suggests that 
the NAV3 gene is a key player in various cancers. Down-
regulation of NAV3 has been found in 40% of primary 
neuroblastomas and in adrenocortical carcinomas (15, 
17), and NAV3 mutations have been found in melanoma 
and pancreatic carcinoma (18). NAV3 belongs to the 
“hill” genes of genomic landscaping associated with 
cancer (19). We have also found NAV3 gene copy num-
ber changes (deletions/amplifications) in some other 
cancer types of epithelial origin (20–21).
As a preliminary study, we undertook to explore the 
usefulness of chromosome 12 aberrations, especially 
Molecular Markers Associated with Clinical Response to Bexarotene 
Therapy in Cutaneous T-cell Lymphoma
Annamari RANkI1, Liisa VäkEVä1, Laura SIPILä2 and kai kROHN2,3
1Department of Dermatology and Allergic Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, 2Dermagene Oy, Tampere, and 3Cli-
niXion Oy, Tampere, and Tampere University Hospital, Tampere, Finland
569Molecular markers associated with bexarotene therapy
copy number changes of the NAV3 gene, as biomar-
kers allowing the detection of chromosomally clonal 
malignant T cells in CTCL patients during bexarotene 
therapy. 
PATIENTS AND METHODS
Patients and skin samples
A total of 21 consecutive patients with proven diagnosis of 
CTCL who were eligible for bexarotene therapy were included. 
Thirteen of the patients had MF stage IB–IVA (i.e. T2N0M0B0–
T4N2M0B1), 4 had folliculotropic MF (T2N0M0–T3b,N0,M0), 
one had CD30+ MF (T3N0M0), two had Sézary syndrome 
and one had peripheral T-cell lymphoma, unclassified (PTCL, 
T3bN1M0). The decision to start bexarotene (Targretin®, Cep-
halon Pharma, Cephalon, Inc., Frazer, PA, USA) therapy was 
based solely on the responsible clinician’s decision, and it was 
a prerequisite (according to the drug licensing) that the patient 
had early-stage CTCL refractory to skin-directed therapy or had 
received at least one standard systemic treatment modality (4) 
with no benefit to the disease. Thus, the patients were allowed 
prior therapy for their CTCL (not with bexarotene). All patients 
provided written informed consent for the skin biopsies obtai-
ned for this study and the study was approved by the Ethical 
Review Board of Helsinki and Uusimaa Hospital District (HUS; 
Dnro 492/E5/05). 
The first skin sample was obtained from a target CTCL skin 
lesion prior to bexarotene therapy. During bexarotene treatment, 
follow-up biopsies from the same target lesion (or skin site if 
the lesion was healed) were obtained 4–6 weeks after the start 
of treatment, irrespective of the clinical response, and after 
5–6 months (if treatment continued) or at the point of treat-
ment cessation or at the point of complete clinical response, 
whichever came first. The skin biopsy was divided in two, one 
half preserved in neutral 4% formalin and processed for routine 
histopathological analysis and the other half also in neutral 4% 
formalin and processed for fluorescence in situ hybridization 
(FISH) analyses. 
Bexarotene therapy
Bexarotene (Targretin®) capsules are indicated for the treat-
ment of skin manifestations of advanced stage CTCL patients 
refractory to at least one systemic treatment. Bexarotene is 
also effective against refractory early-stage CTCL (9). It is 
recommended to start bexarotene at the lower dose of 150 
mg/m2/day and then titrate up to a full dose of 300 mg/m2/
day over 2–4 weeks, while monitoring the lipid values weekly 
(22). Since bexarotene induces hypertriglyceridaemia (and 
hypercholesterolaemia) and central hypothyreosis, concomi-
tant administration of triglyceride-lowering medication and 
thyroxin substitution was given according to guidelines (22). 
Treatment with bexarotene was continued as long as the patient 
experienced benefit. Complete response (CR) was defined as the 
clinical disappearance of all skin (and lymph node if present) 
lesions and partial response (PR) as a 50% or more clearance 
of skin disease from baseline. Progression was defined as the 
appearance of new lesions. 
FISH analyses
Dermagene Oy Ltd (Tampere, Finland) or CliniXion Oy Ltd 
(continuing the business activity of Dermagene) carried out the 
FISH analyses on coded samples for NAV3 and chromosome 12 
on nuclei isolated from the paraffin-embedded skin biopsy samp-
les as previously described (23). Briefly, two bacterial artificial 
chromosome (BAC) clones specific to NAV3 DNA (RP11-36P3 
and RP11-136F16; Research Genetics Inc., Huntsville, AL, USA) 
and the chromosome 12 centromere probe (pA12H8; American 
Type Cell Culture, Manassas, VA, USA) were used and labelled 
with Alexa 594-5-dUTP and Alexa 488-5-dUTP (Invitrogen, 
Carlsbad, CA, USA), respectively. Slides with isolated nuclei 
were allowed to hybridize for 48 h at +37ºC. After the FISH 
procedure, the slides were mounted in Vectashield Mounting 
Medium with 4’,6-diamino-2 phenylindole dihydrochloride 
(DAPI; Vector Laboratories, Burlingame, CA, USA). 
The coded and hybridized FISH slides were analysed by 
two experienced persons, who were blinded to the identity of 
the samples, using Olympus BX61 microscope (Tokyo, Japan) 
equipped with a 60× oil immersion objective and a triple-band 
pass filter for simultaneous detection of Alexa488, Alexa594 
and DAPI (Chroma Technology Corp., Brattleboro, VT, USA). 
Results are indicated as the percentage of NAV3 copy number in 
a total of 200 counted cell nuclei. Cells with two chromosome 
12 signals (diploid cells) and only one signal for NAV3 and cells 
with more than two chromosome 12 signal, but with a lesser 
number of NAV3 signals (e.g. three chromosome 12 centromere 
signals and one NAV3 signal) were interpreted as cells with 
NAV3 deletion. Cells with more NAV3 signals than centromere 
12 signals were interpreted as cells with NAV3 amplification. A 
sample was considered to be NAV3 aberrant if the percentage 
of interphase cells showing amplification was more than 7% or 
the percentage of interphase cells showing deletion was more 
than 4% (calculated from normal distribution of normal sample 
results as mean + 3× standard deviation). 
Lymphocyte cultures
As a reference for proliferating T cells, peripheral blood leuko-
cytes were isolated from two buffy coats, obtained from healthy 
blood donors (Finnish Red Cross Blood Service, Helsinki, 
Finland ) and stimulated with phytohaemagglutin (10 µg/ml in 
RPMI with 10% foetal calf serum (FCS)). Cell aliquots were 
collected at 1, 2, 3 and 4 days of culture, and cytospin prepa-
rations were hybridized with chromosome 12 centromere  and 
NAV3 probes for FISH analyses.
Statistical analyses
For statistical analysis, SPSS statistics 17.0 software was used 
(IBM Corporation, NY, USA). Variables were compared using 
the Fisher’s exact test, because the χ2 test was not valid. All 
p-values are two-sided and exact. 
RESULTS
Clinical responses
A CR was reached in 6 of 21 patients, and a remission 
lasting for more than 24 months was reached in 3 of 
these 6 patients (Table I and Fig. 1). The duration of 
bexarotene therapy to reach CR ranged from one to 24 
months. In one patient, bexarotene was stopped due to 
triglyceride elevation despite maximal dosing of lipid-
lowering drugs. Bexarotene maintenance therapy has 
now continued for more than 5 years in one patient with 
Sézary syndrome and has resulted in a CR. 
A PR was reached in altogether 11 of 21 patients 
(ranging from MF IB/ T2bN0M0) to Sézary syndrome; 
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Table I). In 6 of these, bexarotene maintenance therapy 
has been carried out after the initial treatment period of 
3 months. In the remaining 5 patients (MF IB-IIB, fol-
liculotropic MF and PTCL), a PR was initially reached 
after one to 11 months of bexarotene therapy, but CTCL 
progression followed thereafter. Two of these patients, 
one with MF stage IIB disease (T3N1M0) and another 
with PTCL (T3bN1M0), showed only a limited PR after 
2–3 months of bexarotene, then progressed and died 
soon after (Table I). 
In one patient with early MF, a stable disease 
resulted after 18 months of therapy and the pa-
tient has since continued on a low dose (75–150 
mg/day; 42–84 mg/m2 body surface area/day) 
bexarotene. No response or disease progression during 
bexarotene monotherapy was observed in 3 cases after 
3–12 months of bexarotene (Table I). Two of these 
patients died of CTCL soon afterwards. 
Thus, in summary 15 of the 21 (71%) patients re-
sponded with complete or partial improvement to the 
bexarotene therapy, while in five patients there was no 
response or the patients died of the disease in spite of a 
short initial PR. One patient has remained with stable 
disease. 
Chromosomal copy number changes in relation to 
bexarotene therapy
We observed two types of chromosomal copy number 
alterations in the target skin lesions of these patients. 
Table I. Clinical outcome of patients with cutaneous T-cell lymphoma treated with bexarotene, and fluorescence in-situ hybridization 
assay results of NAV3 and chromosome 12 copy numbers in lesional skin lesions before and during the therapy
Clinical outcome group
Number of patients: 
diagnosis and stage
Duration of bexarotene 
therapy until clinical response 
Percentage of cells with polyploid 
chromosome 12 centromere signals
Cases with allelic NAV3
deletion
CR and remission lasting 
over 24 months 
3: MF IB, MF IIA and 
CD30+ MF
1–24 months 13–32% in biopsies during bexarotene 
therapy (2 patients) and 2% in post-
treatment biopsy
None 
CR 3: two MF IB and one 
SzSa
1.5 months–3 years with low-
dose maintenance in the SzS 
patient 
0–4% None
PR with bexarotene 
maintenance therapy 
6: MF IB–IIA, SS and 
f-MF 
3 months–5 years 0–7% None
PR initially with subsequent 
progression
3: MF IB, MF IIA and 
f-MF
1–11 months In f-MF case: 14% trisomic nuclei (3 
copies of both chromosome 12 and 
NAV3) prior to treatment and 20% post-
treatment
None
PR initially, but subsequent 
death of disease
2: MF IIB and PTCL 2–3 months <4% Both cases: 4% of cells 
with NAV3 deletion
Stable disease 1: MF IB Maintenance with low-dose 3% 4–8% of cells with 
NAV3 deletion 
No response or progression 3: MF IB, MF IIA and 
f-MF
3–12 months 0–3% MF IB: 5% of cells with 
NAV3 deletion in pre-
treatment sample 
aBexarotene stopped due to triglyceride elevation in one patient. 
CR: complete clinical response; PR: partial response; MF: mycosis fungoides; f-MF: folliculotropic MF, SzS: Sézary syndrome; PTCL: peripheral T-cell 
lymphoma.
Fig. 1. Close-up of a mycosis fungoides lesion responding to bexarotene therapy. In this patient, 25–32% of the cell nuclei showed tetrasomic chromosome 
12 and NAV3 copy numbers in samples obtained during treatment. 
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An allelic NAV3 deletion was observed in pretreat-
ment and follow-up samples at low frequency in five 
(24%) patients, 4 of whom showed an initial PR but 
later progressed or died of disease (Table I). The fifth 
patient has remained with stable (T1bN0M0B0) disease 
on low-dose bexarotene maintenance therapy for 2 
years. The observed occurrence of NAV3 deletions in 
cases with clinical progression compared with stable 
cases was statistically significant (Table II, p = 0.011, 
Fisher’s exact test). 
In the group of 15 patients with a clinical response, 3 
patients developed polysomy of chromosome 12 during 
the treatment. In contrast, this aberration was not found 
in any of the cases with clinical progression of disease. 
However, this difference did not reach statistical signi-
ficance (p = 0.526). Tetraploidy of chromosome 12 was 
consistently found in the skin lesions of two of the three 
patients reaching CR and remaining in remission. Three 
copies of chromosome 12 and NAV3, respectively, were 
detected in one of the 12 patients with PR. Allelic NAV3 
amplification in association with a normal number of 
chromosome 12 was not found. 
When normal blood donor lymphocytes were stimu-
lated with phytohaemagglutinin (PHA), and analysed 
with the same FISH assay, 2–3% of the large lympho-
blasts at 3 and 4 day cultures showed similar tetraploidy 
as in some of the patient samples (4 chromosome 12 
centromere and 4 NAV3 labels; Fig. 2). We thus con-
clude that the observed tetraploidy of chromosome 12 
and NAV3 in the patient samples is likely to reflect a 
proliferative anti-tumour response among the infiltrating 
lymphocytes. 
DISCUSSION
The common problem with cancer therapies, even with 
the most recent ones, is that only a proportion of pa-
tients will respond with a clearly favourable outcome 
resulting in remission. There is thus an urgent need for 
novel biomarkers to identify patients who are likely 
to respond to a given therapy. Since NAV3 is a novel 
cancer-associated gene (24) previously reported to 
show allelic deletion in CTCL (11, 12), brain tumours 
(25) and colorectal cancer (21), we anticipated that 
it might serve as a new biomarker allowing for the 
detection of chromosomally clonal malignant T cells 
in CTCL patients during bexarotene therapy and thus 
for monitoring the therapeutic effect of, for example, 
bexarotene. 
Initially, a non-balanced allelic deletion of NAV3 was 
observed in a substantially high proportion of CTCL 
patients (11). Subsequently, we and others (14) have 
shown (by using the current validated FISH method) 
that the percentage of NAV3-deleted cases in CTCL 
is in fact lower, in the order of 20%. In addition, in 
the current bexarotene-therapy patient material, 24% 
showed allelic deletion of NAV3, although at a low 
level, before and during the treatment. The patients 
with NAV3 deletion mostly belonged to the group of 
non-responders or to those with progressive disease 
after a partial early response. In contrast, the appearance 
of cell clones with tetraploid signals for NAV3 and for 
the corresponding chromosome 12 during the first few 
months of bexarotene therapy seemed to be associated 
with the most favourable clinical response, longstanding 
Fig. 2. Example of NAV3 (red signal) 
and chromosome 12 (green signal) 
fluorescence in-situ hybridization (FISH) 
on PHA-stimulated normal human 
lymphocytes showing 4 signals of both 
chromosome 12 and NAV3 in some nuclei. 
Right-hand panel: cell in the initiating 
phase of cell division. 
Table II. Summary of chromosome 12 and NAV3 copy number alterations in relation to bexarotene therapy response
Patients, n Polysomy of chromosome 12 and corresponding NAV3 amplification Allelic NAV3 deletion
Overall clinical response 15 3 (20%) 1 (7%)* (stable disease)
Disease progression or died of disease 6 0 (0%) 4 (67%)*
*p = 0.011, Fisher’s exact test.
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remission, in this small patient material. An indication 
that the tetraploid cells observed in the patient samples 
could represent a proliferating normal T-cell population 
is the fact that similar large lymphoblastoid cells with 
four copies of chromosome 12 were also observed in 
the normal lymphocytes, stimulated for a proliferative 
response with the PHA mitogen.
CTCL lesions are characterized by a low number of 
truly malignant cells and a larger population of reactive 
T-cells that have been proposed to exert a cytotoxic 
immune response towards the malignant cells (26–28). 
Also, as shown by recent proteome-based studies, sero-
reactivity against lymphoma cells can be found in CTCL 
patients, although these responses are restricted to few 
antigens and are heterogeneous in nature (29). Thus, our 
observation of chromosome 12 tetraploidy in the skin 
lesions of two of three patients with CR and remaining 
in remission, and polyploidy in one of 12 patients with 
PR, could be considered as a marker of the proliferation 
of either regulatory or cytotoxic T cells directed against 
the malignant lymphocytes. 
On the other hand, the observed low-level NAV3 dele-
tion in 5 patients, 4 of whom did not respond to therapy, 
or who showed only an initial PR, and progressed or died 
of disease, would indicate that the consequences of the 
NAV3 deletion may have an effect not only on the cancer 
cells as such, but also on the immune response targeted 
against the cancer cells. The predicted function of NAV3 
indicates that it might act as a transcription factor, and 
recent evidence identifies NAV3 as a member of the hu-
man Navigator proteins, which function as microtubule 
plus-end tracking proteins (+TIPs), which in turn are 
involved in many cellular processes, including mitosis, 
and cell migration (30). We have recently shown that 
silencing NAV3 induces the expression of, for example, 
IL23R, a key membrane molecule in inflammatory re-
sponses and associated with the JAk/STAT signalling 
pathway (http://www.ncri.org.uk/ncriconference: LB15). 
The activation of the IL23/IL23R-dependent JAk/STAT 
pathways may lead to the emergence of Treg cells that 
would inhibit the possible anti-cancer immune response 
(30). An abnormal IL-23 expression has been suggested 
to play a role in the patho genesis and progression of MF/
SS (31). Interestingly, retinoic acid has been shown to 
inhibit the expression of IL-23R (as well as IL-6Ralpha 
and IRF-4) and consequently, also Th17 development 
(32–33). Thus, further prospective studies on this pat-
hway axis would be warranted in connection of bexaro-
tene therapy. The results of this study, although a limited 
number of patients were involved, are in line with our 
earlier studies on the clinical consequences of NAV3 
copy number changes. Although the exact molecular 
and cellular mechanism behind the observed tetrasomy 
of chromosome 12 and bexarotene therapy is unknown, 
the indication of a favourable clinical response in such 
cases, especially in comparison with a clearly less fa-
vourable outcome in patients harbouring NAV3 deletions, 
warrants further prospective and more detailed studies 
on these potential new biomarkers. 
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